Adrian Velazquez-Campoy1, Sonia Vega2, Oscar Sanchez-Gracia3, Angel Lanas4, Alberto Rodrigo5, Alagammai Kaliappan6, Melissa Barousse Hall6, Taylor Q Nguyen6, Guy N Brock7, Jason A Chesney6, Nichola C Garbett8, Olga Abian9. 1. Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza 50018, Spain; Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza, Zaragoza 50009, Spain; Aragon Institute for Health Research (IIS Aragon), Zaragoza, 50009, Spain; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Fundacion ARAID, Government of Aragon, Zaragoza 50018, Spain. Electronic address: adrianvc@unizar.es. 2. Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza 50018, Spain. 3. Enrique Val, Zaragoza 50011, Spain. 4. Aragon Institute for Health Research (IIS Aragon), Zaragoza, 50009, Spain; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, 50009, Spain; Department of Medicine, University of Zaragoza, Spain. 5. Department of Medicine, University of Zaragoza, Spain. 6. James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, KY 40202, USA. 7. Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. 8. James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, KY 40202, USA. Electronic address: nichola.garbett@louisville.edu. 9. Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza 50018, Spain; Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza, Zaragoza 50009, Spain; Aragon Institute for Health Research (IIS Aragon), Zaragoza, 50009, Spain; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza 50009, Spain. Electronic address: oabifra@unizar.es.
Abstract
BACKGROUND: Differential Scanning Calorimetry (DSC) is a technique traditionally used to study thermally induced macromolecular transitions, and it has recently been proposed as a novel approach for diagnosis and monitoring of several diseases. We report a pilot study applying Thermal Liquid Biopsy (TLB, DSC thermograms of plasma samples) as a new clinical approach for diagnostic assessment of melanoma patients. METHODS: Multiparametric analysis of DSC thermograms of patient plasma samples collected during treatment and surveillance (63 samples from 10 patients) were compared with clinical and diagnostic imaging assessment to determine the utility of thermograms for diagnostic assessment in melanoma. Nine of the ten patients were stage 2 or 3 melanoma subjects receiving adjuvant therapy after surgical resection of their melanomas. The other patient had unresectable stage 4 melanoma and was treated with immunotherapy. Two reference groups were used: (A) 36 healthy subjects and (B) 13 samples from 8 melanoma patients who had completed successful surgical management of their disease and were determined by continued clinical assessment to have no evidence of disease. RESULTS: Plasma thermogram analysis applied to melanoma patients generally agrees with clinical evaluation determined by physical assessment or diagnostic imaging (~80% agreement). No false negatives were obtained from DSC thermograms. Importantly, this methodology was able to detect changes in disease status before it was identified clinically. CONCLUSIONS: Thermal Liquid Biopsy could be used in combination with current clinical assessment for the earlier detection of melanoma recurrence and metastasis. GENERAL SIGNIFICANCE: TLB offers advantages over current diagnostic techniques (PET/CT imaging), limited in frequency by radiation burden and expense, in providing a minimally-invasive, low-risk, low-cost clinical test for more frequent personalized patient monitoring to assess recurrence and facilitate clinical decision-making.
BACKGROUND: Differential Scanning Calorimetry (DSC) is a technique traditionally used to study thermally induced macromolecular transitions, and it has recently been proposed as a novel approach for diagnosis and monitoring of several diseases. We report a pilot study applying Thermal Liquid Biopsy (TLB, DSC thermograms of plasma samples) as a new clinical approach for diagnostic assessment of melanomapatients. METHODS: Multiparametric analysis of DSC thermograms of patient plasma samples collected during treatment and surveillance (63 samples from 10 patients) were compared with clinical and diagnostic imaging assessment to determine the utility of thermograms for diagnostic assessment in melanoma. Nine of the ten patients were stage 2 or 3 melanoma subjects receiving adjuvant therapy after surgical resection of their melanomas. The other patient had unresectable stage 4 melanoma and was treated with immunotherapy. Two reference groups were used: (A) 36 healthy subjects and (B) 13 samples from 8 melanomapatients who had completed successful surgical management of their disease and were determined by continued clinical assessment to have no evidence of disease. RESULTS: Plasma thermogram analysis applied to melanomapatients generally agrees with clinical evaluation determined by physical assessment or diagnostic imaging (~80% agreement). No false negatives were obtained from DSC thermograms. Importantly, this methodology was able to detect changes in disease status before it was identified clinically. CONCLUSIONS: Thermal Liquid Biopsy could be used in combination with current clinical assessment for the earlier detection of melanoma recurrence and metastasis. GENERAL SIGNIFICANCE: TLB offers advantages over current diagnostic techniques (PET/CT imaging), limited in frequency by radiation burden and expense, in providing a minimally-invasive, low-risk, low-cost clinical test for more frequent personalized patient monitoring to assess recurrence and facilitate clinical decision-making.
Authors: Shesh N Rai; Sudhir Srivastava; Jianmin Pan; Xiaoyong Wu; Somesh P Rai; Chongkham S Mekmaysy; Lynn DeLeeuw; Jonathan B Chaires; Nichola C Garbett Journal: PLoS One Date: 2019-08-20 Impact factor: 3.240
Authors: Sonia Hermoso-Durán; Guillermo García-Rayado; Laura Ceballos-Laita; Carlos Sostres; Sonia Vega; Judith Millastre; Oscar Sánchez-Gracia; Jorge L Ojeda; Ángel Lanas; Adrián Velázquez-Campoy; Olga Abian Journal: J Pers Med Date: 2020-12-31
Authors: Ferdinanda Annesi; Sonia Hermoso-Durán; Bruno Rizzuti; Rosalinda Bruno; Domenico Pirritano; Alfredo Petrone; Francesco Del Giudice; Jorge Ojeda; Sonia Vega; Oscar Sanchez-Gracia; Adrian Velazquez-Campoy; Olga Abian; Rita Guzzi Journal: J Pers Med Date: 2021-04-13
Authors: Svetla Todinova; Sashka Krumova; Desislava Bogdanova; Avgustina Danailova; Elena Zlatareva; Nikolay Kalaydzhiev; Ariana Langari; Ivan Milanov; Stefka G Taneva Journal: Biomolecules Date: 2021-10-12